Ann: Changes to Company Securities, page-26

First 26 Last

Share
Profile

Follow
mpk1980

1,549 Posts.

429

29/04/20

09:04

Post #: 44315014
Share

Originally posted by Kgre ↑

I saw what you responding to; I wrote it. ???

"Do you understand that A3D is currently printing samples for those who have shown interest under NDAs. Maybe you should take the time to visit their offices/warehouse and see it for yourself."
Doesn't sound like a question so much as a patronising bit of rhetoric.
But I'll answer it like a question anyway. How long does it take to design and print a part? 24 hours?
And, how long does it take DNV-GL to stress test a metallurgy. About same, but lets allow 7 of the same part tested to breaking point.

So now, you tell me....
Why haven't you seen the results yet? Or a client?
The only explanation I can come up with is: the parts don't meet spec. This company has demonstrated REPEATEDLY AND CONSISTENTLY that is not keeping you informed, when information is detrimental to the image shareholders have of a disruptive tech company.

$430 million value lost from its peaks. Thats 97%.
It tells you not only management, but also about the tech. There is ZERO evidence that the tech is any good, and loads that is isn't. And opportunites abound on ASX now, for bags in reputable, revenue earning companies.

The next cap raise will be an offer to retail holders, an SPP because there's nothing left here for sophs to pick over, and far better opportunites.
And the faithful will say "Wow, look the company is finally giving us long term holders a fair go".

Expand

Have a VERY good read of the announcement titled "Major Step Towards MCP Process Validation." That's independent test results!

A3D Price at posting: 9.4¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

LDX

Lumos gains US govt support for study on FebriDx bacterial infection test

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

ETM

Energy Transition Mins' frustrated as mammoth lawsuit against Greenland inches forward; shares dip -12%

There are more pages in this discussion • 2 more messages in this thread...

First 26 Last

Add A3D (ASX) to my watchlist

(20min delay)
Last 7.5¢		Change 0.000(0.00%)		Mkt cap ! $28.30M

Open	High	Low	Value	Volume
7.7¢	7.7¢	7.5¢	$99.70K	1.310M

Buyers (Bids)

No.	Vol.	Price($)
3	835312	7.5¢

Sellers (Offers)

Price($)	Vol.	No.
7.6¢	1109	1

View Market Depth

No.	Vol.	Price($)
2	701981	0.075
4	748320	0.074
1	150000	0.073
3	176944	0.072
1	8408	0.071

Price($)	Vol.	No.
0.077	57685	1
0.078	124939	2
0.079	47000	1
0.080	226177	3
0.084	100000	1

Last trade - 11.16am 03/10/2024 (20 minute delay)

A3D (ASX) Chart

Ann: Changes to Company Securities, page-26

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Lumos gains US govt support for study on FebriDx bacterial infection test

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Energy Transition Mins' frustrated as mammoth lawsuit against Greenland inches forward; shares dip -12%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Changes to Company Securities, page-26

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Lumos gains US govt support for study on FebriDx bacterial infection test

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Energy Transition Mins' frustrated as mammoth lawsuit against Greenland inches forward; shares dip -12%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News